Back

Effect of guideline-recommended medical therapy according to blood urea nitrogen

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - treatment 5 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Paolo Tolomeo

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
The impact of modifiable risk factors on readmissions during the vulnerable period in patients with heart failure
Assistant Professor A. Lacraru (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
AZD3427, a relaxin mimetic in pulmonary hypertension group 2 associated with left heart disease: design and rationale of the phase 2b Re-PHIRE Study
Professor M. Ufnal (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Effect of intravenous FCM therapy on myocardial work indices in patients with HFrEF and ID.
Professor A. Safarova (Baku, AZ)
Abstract Slides Video
Presentation thumbnail
Prospective evaluation of sacubitril/valsartan utilization patterns and clinical outcomes in Korean patients with heart failure with reduced ejection fraction: real-world post-marketing surveillance
Professor J. Choi (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
ARNi treatment in adults with Tetralogy of Fallot: a single-centre experience
Doctor A. Ferreira (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - treatment 5

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Low levels of irisin predicted worsening kidney function in dapagliflozin-treated patients with chronic heart failure and concomitant type 2 diabetes mellitus
thumbnail
Congress Presentation
Comparison of NT-ProBNP levels in different groups of chronic heart failure: preliminary data analysis of research
thumbnail
Congress Presentation
Dapaglifozin in advanced heart failure patients : effects on congestion, NTproBNP and cardiorenal outcome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources